LENZ Therapeutics (LENZ) Other Non-Current Liabilities (2020 - 2024)

LENZ Therapeutics (LENZ) has 5 years of Other Non-Current Liabilities data on file, last reported at $111000.0 in Q1 2024.

• Other Non-Current Liabilities for Q1 2024 came in at $111000.0, down 87.26% year-over-year; the trailing twelve-month figure through Mar 2024 was $111000.0 (down 87.26% YoY), and the FY2023 annual result was $871000.0, down 91.95% from the prior year.
• Other Non-Current Liabilities declined to $111000.0 in Q1 2024 per LENZ's latest filing, from $871000.0 in the prior quarter.
• Over five years, Other Non-Current Liabilities peaked at $10.8 million in Q4 2022 and troughed at $64000.0 in Q2 2021.
• A 5-year average of $1.9 million and a median of $593500.0 in 2020 frame the typical range for Other Non-Current Liabilities.
• The sharpest annual moves came in 2022 and 2023: Other Non-Current Liabilities jumped 3676.56% in 2022, then plunged 91.95% in 2023.
• A 5-year view of Other Non-Current Liabilities shows it stood at $316000.0 in 2020, then slumped by 79.75% to $64000.0 in 2021, then soared by 16804.69% to $10.8 million in 2022, then sank by 91.95% to $871000.0 in 2023, then tumbled by 87.26% to $111000.0 in 2024.
• Business Quant data shows LENZ's Other Non-Current Liabilities at $111000.0 in Q1 2024, $871000.0 in Q4 2023, and $871000.0 in Q1 2023.